Skip to main content Skip to search Skip to main navigation

Brief spots on autumn conferences

PDA and ISPE offered virtual conferences with interesting insights in September 2020

5 min. reading time | by Thomas Peither
Published in LOGFILE 47/2020

In September 2020 the series of virtual autumn conferences of PDA and ISPE started. We were present and pick out some excellent sessions with this LOGFILE feature.


The most critical ICH revision: ICH Q9

The conference season started in September with the virtual PDA/FDA Joint Regulatory Conference. Sabine Paris followed among others the intriguing lecture of of Roger Nosal, Pfizer and Rapporteur of the ICH Quality Discussion Group.

He presented a schedule for the ICH Q9 Quality Risk Management Revision, with the final revision expected in June 2022. Details are shown in the figure.

Nosal described the revision as the "most critical revision", as quality risk management now plays a leading role in many topics.

The objectives of the revision are adjustments to specific chapters and annexes of the current guideline and the development of specific training materials for the proposed revisions.

The adjustments shall cover e.g.:

  • High levels of subjectivity in risk assessment and in QRM outputs
  • Product availability risks
  • Lack of understanding as to what constitutes formality in QRM work
  • Lack of clarity on risk-based decision-making

"The prepared mind will be the catalyst of change."

A few days later the virtual ISPE Europe Annual Conference demonstrated a strong and robust understanding of GMP in Europe.

Udo Vetter, Chairman of the Advisory Board, Vetter Pharma, presented the keynote and he covered the topic "How to Run a Pharma Production in a Pandemic Situation".

He focused on many aspects in a pandemic situation. Are companies really prepared? Is there a special pandemic team in the company?

The supply chain is a critical process for every company. Are we prepared to use different suppliers if the usual suppliers fail? What happens if transport routes are closed (roads, air traffic)?

Employees no longer work in the office, but from home. How is the return to the office organised? The quality of leadership is demonstrated by the way companies take care of their employees!

Communication with customers and suppliers is more important than ever in this situation.

Udo Vetter predicted that we can only return to previous normality after 18-24 months. By then, the new normality will be normal with all the difficulties we have to overcome.

He ended his presentation with the view: "The prepared mind will be the catalyst of change. Controlled fashioned change will be the new way. The old way will not return."


Continuous Manufacturing has arrived at the shop floor!

John Groskoph, Executive Director, Global CMC at Pfizer, showed very well how virtual presentations can be optimally designed. In his presentation on continuous manufacturing, he used videos and good visualizations to convey his ideas. He used a manufac­turing unit to demonstrate how continuous manufac­turing can work today.

What did we learn during the presentation?

Continuous Manu­facturing has already arrived at the manufacturing stage and can be applied –there are no excuses not to do it. Let's get down to business!

The presented project started in 2016. Today, the resulting commercial facility has been inspected several times by authorities.


Panel discussions are big benefits in virtual conferences.

Some quotes from international regulators, who gave insights into their work and expectations in pandemic times:

“We were surprised and a little disappointed about the reaction of the industry.”

“It is crucial to improve the remembrance on these experiences we made in the last months. In future we should be better prepared.”

Another opinion was that “nobody was well prepared on this situation. We never expected to be impacted on all areas we have to handle and to have a world-wide knock-down.”

“A plus point for industry was the great effort to find treatments and vaccines for the coronavirus. We can say that industry and regulators step up to bring products on the table.”

“It is not over yet and there are still challenges in front of us.”

“PIC/S is very important and an opportunity for the collaboration of regulators.”

“There will be an impact on the cost for medicinal drug products – will the patients pay for this cost increase?”


Distant Assessment and remote GMP inspections

Another highly interesting panel discussion focused on distant assessments and remote GMP inspections. The participants represented EMA, France, UK, PIC/S, Germany, Switzerland, Australia, Italy, Russia.

It's not possible to summarize this one-hour discussion in a post. Some important outcomes are:

  • We need harmonization of remote inspection!
  • There is a need for guidance (for authorities and industry)!
  • Terminology is a key to discuss the same issues!
  • How do we ensure mutual trust?

Monika Mayr announced that EMA prepared a guideline on that topic. Many participants see hybrid inspections as a possible solution.


Summary

Virtual conferences can be innovative if the possibilities are fully exploited. In many cases, both the organisers and the speakers have yet to embrace these formats. The longer the pandemic lasts, the more improvements we will see in the exchange of knowledge. It is to be hoped that the good of the new will be preserved.


Do you have any questions or suggestions? Please contact us at: redaktion@gmp-verlag.de

Thomas Peither
Thomas Peither

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next

Related Products

Skip product gallery
GMP Compliance Adviser | Named User Licence | 12M

GMP Compliance Adviser | Named User Licence | 12M

With an named user licence, one user can access the knowledge portal; with a corporate licence, any number of users can access it.Approx. 5,000 pages of practical GMP knowledge with illustrations and forms: Practical guidance for rapid implementation in the workplaceDetailed descriptions of GMP-compliant systemsInternational laws and guidelines Always up-to-date thanks to regular updates Download Advantages and Prices60+ Sample Documents In addition, the GMP Compliance Adviser contains more than 60 sample documents (MS Office) and practical examples that you can use.Sample SOPsSample FormsSample ReportsSample DocumentationChecklistsProcess Diagrams (Flowcharts)Practical Examples of QRM Application (e.g., Risk Analyses)Sample Documents for Qualification and ValidationCase StudiesWritten by more than 80 authors with hands-on experience directly linked to the industryA team of over 80 experts interpret regulatory requirements and describe how they are implemented in practice.The authors are experienced in the pharmaceutical industry, consulting, and government agencies.

delivery immediately after receipt of payment
€1,368.00 net excl. VAT
GMP:KnowHow Pharma Logistics (GDP) | Named User Licence | 12M

GMP:KnowHow Pharma Logistics (GDP) | Named User Licence | 12M

Your knowledge portal for GDP-compliant pharmaceutical logistics.  It is important that you as a logistics service provider, but also as a client in the pharmaceutical industry, comply with regulatory requirements. The GMP:KnowHow knowledge portal guides you through the complex regulatory landscape of the pharmaceutical and logistical supply chain! The knowledge portal gives you an easy-to-understand overview of all the important topics. Interactive graphics help you navigate all areas covered by the EU GDP Guidelines (2013/C 343/01). You also have the relevant passages of the regulations directly at hand for each topic. This allows you to compare the requirements directly and saves valuable research time.One thing is certain: the knowledge portal answers your questions about the supply chain of medicinal products, active pharmaceutical ingredients and medical devices. You don't have to be an expert. Yet.You will find answers to your questions in the GMP:KnowHow Pharma Logistics (GDP). Where does GDP begin, where does GMP end? What does GDP-compliant mean? When do I also have to take GMP requirements into account? What permits do I need for certain activities? What requirements do I have to fulfil? What is the current legal basis? How am I covered? What authorizations do I have for my work, e.g. from my employer? Who is responsible — the client or the contractor? And many more What is the difference to the GMP Compliance Adviser? GMP:KnowHow Pharma Logistics (GDP) is a practical knowledge portal dedicated to Good Distribution Practice (GDP). It is a product that is independent of the GMP Compliance Adviser and concentrates on content that is essential for carriers of medicinal products, active pharmaceutical ingredients and medical devices as well as for logistics clients. The focus is on practical knowledge and how to apply it in your daily business. If necessary, the relevant regulations can be called up immediately alongside the practical knowledge, and you can see the relevant paragraphs at a glance. In addition, sample documents are available to help you make immediate progress. AuthorSimone Ferrante, currently Director Quality at Fisher Clinical Services, previously served as Head of Quality Control and Responsible Person (GDP) for the Grieshaber Group. She is also a long-standing author and GDP expert at GMP-Verlag.

delivery immediately after receipt of payment
€610.00 net excl. VAT
E-Learning GMP:READY | Specialist Knowledge GMP for Engineers

E-Learning GMP:READY | Specialist Knowledge GMP for Engineers

Why are GMP rules important for technicians and engineers? Technicians and engineers play a key role in ensuring compliance with Good Manufacturing Practice (GMP) standards. They are involved in critical activities such as: planning and construction of ventilation systems, maintenance of water treatment plants, calibration of measuring sensors. Therefore, they are jointly responsible for the quality of medicines and must ensure that their work complies with GMP standards.Your advantages: Fast familiarization with GMP topics in approx. 2 hours, time- and location-independent online training, printable personal certificate, 12-month access for initial and follow-up training, automatic updates in case of legal changes,content compliant with Article 7(4) of Directive 2003/94/EC.The Author This e-learning course was developed with the collaboration of Dipl.-Ing. Andreas Nuhn (D & B Pharmadesign GmbH).

delivery time appr. 2-5 workdays after receipt of payment
€245.00 net excl. VAT
GMP Fundamentals | A Step-by-Step Guide

GMP Fundamentals | A Step-by-Step Guide

This handbook is a practical and easy to read guideline, giving you a quick and comprehensive overview of the complex world of Good Manufacturing Practice (GMP) without the need of previously acquired knowledge. Some topics are: GMP: Purpose and basic pharmaceutical terms Laws, licenses and inspections Personnel: Responsibility and hygiene Standard Operating Procedures (SOP) and documentation Design of rooms and facilities Processing and packaging Quality control and market release Suppliers, storage and logistics (Good Distribution Practice = GDP) Alphabetical index and abbreviations Using practical examples and comparisons to every-day life will help to easy understand GMP regulations.GMP Fundamentals is a helpful guide which facilitates the entry into the GMP world and teaches the necessary basics.

delivery immediately after receipt of payment
€44.90 net excl. VAT